Irisin and troponin I expression in dialysis patients submitted to remote ischemic preconditioning: a pilot study

Expressão de irisina e troponina I em pacientes em diálise submetidos a pré-condicionamento isquêmico remoto: um estudo piloto

ABSTRACT

Background: Renal replacement therapy continues to be related to high hospitalization rates and poor quality of life. All-cause morbidity and mortality in renal replacement therapy in greater than 20% per year, being 44 times greater when diabetes is present, and over 10 times that of the general population. Regardless of treatment, the 5-year survival is 40%, surpassing many types of cancers. Irisin is a hormone that converts white adipose tissue into beige adipose tissue, aggregating positive effects like fat mass control, glucose tolerance, insulin resistance, prevention of muscle loss, and reduction in systemic inflammation. Objectives: To determine the serum levels of troponin I in hemodialysis patients submitted to remote ischemic preconditioning (RIPC) associated with irisin expression. Methods: This was a prospective, randomized, double-blind clinical trial with patients with chronic kidney disease submitted to hemodialysis for a 6-month period. Troponin I, IL-6, urea, TNF-α, and creatinine levels were determined from blood samples. The expressions of irisin, thioredoxin, NF-κb, GPX4, selenoprotein and GADPH were also evaluated by RT-PCR. Results: Samples from 14 hypertensive patients were analyzed, 9 (64.3%) of whom were type 2 diabetics, aged 44-64 years, and 50% of each sex. The difference between pre- and post-intervention levels of troponin I was not significant. No differences were verified between the RIPC and control groups, except for IL-6, although a significant correlation was observed between irisin and troponin I. Conclusion: Remote ischemic preconditioning did not modify irisin or troponin I expression, independent of the time of collection.

Keywords: Renal Dialysis; Hypertension; Diabetes Mellitus; Blood Chemical Analysis; Troponin I.

RESUMO

Introdução: A terapia de substituição renal continua associada a altas taxas de hospitalização e baixa qualidade de vida. A morbimortalidade por todas as causas na terapia de substituição renal é superior a 20% ao ano, sendo 44 vezes maior quando a diabetes está presente e mais de 10 vezes a da população em geral. Independente do tratamento, o sobrevivente de 5 anos é de 40%, superando muitos tipos de câncer. A irisina é um hormônio que converte tecido adiposo branco em tecido adiposo bege, agregando efeitos positivos como o controle de massa gorda, tolerância à glicose, resistência à insulina, prevenção de perda muscular e redução da inflamação sistêmica. Objetivos: Determinar os níveis séricos de troponina I em pacientes em hemodiálise submetidos ao pré-condicionamento isquêmico remoto (PCIR) associado à expressão de irisina. Métodos: Estudo clínico prospectivo, randomizado, duplo-cego, com pacientes com doença renal crônica submetidos à hemodiálise por um período de 6 meses. Os níveis de troponina I, IL-6, uréia, TNF-α e creatinina foram determinados a partir de amostras de sangue. As expressões de irisina, tioredoxin, NF-κb, GPX4, selenoproteína e GADPH foram também avaliadas por RT-PCR. Resultados: Foram analisadas amostras de 14 pacientes hipertensos, 9 (64,3%) dos quais eram diabéticos tipo 2, com idades entre 44 e 64 anos e 50% de cada gênero. A diferença entre os níveis pré e pós-intervenção de troponina I não foi significativa. Não houve diferenças entre os grupos PCIR e controle, exceto pela IL-6, embora tenha sido observada correlação significativa entre irisina e troponina I. Conclusão: O pré-condicionamento isquêmico remoto não modificou a expressão de irisina ou troponina I, independentemente do tempo de coleta.

Palavras-chave: Diálise Renal; Hipertensão; Diabetes Mellitus; Análise Química do Sangue; Troponina I.
**INTRODUCTION**

Despite the recent improvements in the dialysis process, renal replacement therapy continues to present high hospitalization rates, which is related to poor quality of life. All-cause morbidity and mortality in renal replacement therapy is greater than 20% per year, being 44 times greater when diabetes is present and over 10 times that of the general population\(^1\,\text{,}\,\text{2}\). Regardless of treatment, the 5-year survival is 40%, which surpasses that of numerous types of cancers\(^3\,\text{,}\,\text{4}\). In hemodialysis patients, cardiovascular mortality accounts for 40% of all deaths, mostly due to heart failure, acute myocardial infarction, and fatal cardiac arrhythmia\(^5\,\text{,}\,\text{4}\). During prolonged treatment, these patients are susceptible to morphofunctional alterations. Quantification of myocardial blood flow (MBF) by positron emission tomography (PET) during hemodialysis of patients with no significant angiographic coronary lesion evidence alterations in the left ventricular (LV) segmental contraction that were correlated with the reduction in both global and segmental MBF, promoting contractile dysfunction\(^6\). Reduction in segmental MBF is associated with circumscribed areas of necrosis, altered permeability, elevated circulating levels of cardiac troponin (cTnT), together with LV hypokinetic regions detected by echocardiography. Recurrent ischemic episodes during hemodialysis promote myocardial injury with functional irreversibility\(^6\).

Myocardial ischemia can be triggered by several factors: high prevalence of coronary atheroma, left ventricular hypertrophy, intradialytic hypotension, and reduced reserve coronary flow (RRF), even in the absence of stenosis\(^7\,\text{,}\,\text{8}\). Left ventricular hypertrophy (LVH), which often occurs in renal failure, increases the ventricular end-diastolic pressure, the parietal stress that compromises MBF, particularly in the subendocardium\(^9\). Myocardial stunning of LV dysfunction due to transient ischemia associated with hemodialysis is frequently prolonged but reversible\(^6\,\text{,}\,\text{10}\). Ischemic episodes due to hemodialysis play an important role in the development of heart failure and cardiac arrhythmias\(^11\,\text{,}\,\text{12}\). Thus, reducing ischemia following hemodialysis seems to be a desirable therapeutic target\(^13\).

Irisin is a hormone identified in muscle cells of transgenic mice expressed by Ppargc1a, which encodes the co-activator-\(\alpha\) of the \(\gamma\) receptor activated by peroxisome proliferator (PGC-1\(\alpha\)). In turn, PGC-1\(\alpha\) stimulates the gene expression of the transmembrane protein fibronectin type III domain-containing protein 5 (Fndc5). When Fndc5 undergoes proteolytic cleavage, it is released into the bloodstream with a fragment containing 112 residual amino acids. It binds to unidentified receptors on the cell surface of adipose tissue\(^14\). Irisin converts white adipose tissue into beige adipose tissue, which aggregates positive effects like fat mass control, glucose tolerance, insulin resistance, prevention of muscle loss, and reduction in systemic inflammation\(^15\,\text{,}\,\text{16}\). Irisin has the therapeutic potential to prevent and treat obesity and diabetes\(^17\). In humans, FNDC5 is strongly expressed in skeletal muscle, heart, tongue, and rectum. FNDC5 expression is decreased in the pancreas, liver, and organs involved in glycolytic homeostasis\(^18\). In humans, FNDC5 expression in adipose tissue is up to 200 times lower than that of skeletal muscle\(^18\,\text{,}\,\text{19}\). Circulating levels are modulated by factors that include diet, obesity, exercise, pharmacological agents, and different pathological conditions. Remote ischemic preconditioning (RIPC) is a non-invasive, non-pharmacological intervention of myocardial protection induced by transient interruption of the blood flow in one limb by a blood pressure cuff, which shows a protective effect against myocardial ischemia (reperfusion injury)\(^18\,\text{,}\,\text{20}\,\text{,}\,\text{21}\). RIPC is associated with a reduction in troponin I release, lower elevation in the ST segment of the ECG, and lower adverse cardiovascular events following percutaneous coronary intervention (PCI)\(^19\,\text{,}\,\text{22}\). In coronary artery bypass graft surgery, RIPC was shown to significantly reduce the release of cardiac troponin (cTnT) 6, 12, 24, and 48 h after the surgical procedure\(^11\,\text{,}\,\text{23}\). This study aimed to determine the behavior of serum troponin I levels in hemodialysis patients submitted to RIPC associated with irisin expression.

**MATERIALS AND METHODS**

A prospective, randomized, double-blind clinical trial was conducted by the Laboratory of Clinical Analysis of ABC Medical School (FMABC), in patients with chronic renal disease under hemodialysis for a period of six months. The procedures followed the principles of the Declaration of Helsinki and were approved by the Research Ethics Committee of Paulista University (UNIP), under protocol no. 2.424.258. Eligibility consisted of patients submitted to outpatient hemodialysis therapy, who were 18 years old or over, and diagnosed with chronic renal failure according to the Kidney Disease Initiative for Global Outcomes (KDIGO). Patients who presented neoplasia, infection, and were HIV+ were excluded. Blood samples were collected to determine troponin I levels using quantitative immunochromatographic methods (Human Quit). IL-6 and TNF-\(\alpha\) were analyzed.
using a chemiluminescent immunoenzymatic method (Simens). Urea and creatinine quantifications were performed using a colorimetric enzymatic method in a fully automated spectrophotometer (COBAS 6000 Roche). Good practices in clinical analysis were followed in all analyses performed in this study. For analysis of gene expression, RNA was extracted using the Trizol® technique. One microgram of cDNA was converted using the Invitrogen Reverse Transcriptase Superscript II RNAse kit, according to the manufacturer’s recommendations.

The qRT-PCR technique was applied to the cDNA sequence obtained so that irisin GADPH, thioredoxin, NF-κB, GPX4, and selenoprotein could be analyzed as follows: 1X of buffer 2X SYBR Green PCR Master Mix, 2.0 μL of cDNA and 0.4 mM of RT-PCR Primer Assay resulting in 15 μL of final reaction volume. The volume was completed using deionized water. The reaction was run in a Cycler 7500 (Applied Biosystems) using the following program: 95°C for 10 min; 40 cycles of 95°C for 15 s and 60°C for 60 s. The sequence of primers used is presented in Table 1.

The intervention group was submitted to RIPC on the right arm using a sphygmomanometer at 200 mmHg for 5 min, followed by 5 min of deflation, repeated three times for a total of 30 min, during three consecutive hemodialysis sessions. The control group was not submitted to any additional intervention. Blood samples were collected before the start of the first and third weekly sessions. Blood urea nitrogen (BUN) was measured to calculate the single pool Kt/v, and irisin and troponin I to assess cardiac compromise due to hemodialysis. The primary outcome was mortality, while the secondary outcomes were acute myocardial infarction, stroke, and thromboembolic event. Serum levels of TNF-α, selenoprotein, thioredoxin, and NFκB indicated an inflammatory profile. Urine samples were taken to determine the albumin/creatinine ratio and beta-trace protein (BTP) of the first urination. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease Study equation for adults.

**Statistical analysis**

Qualitative variables are presented as absolute and relative frequency. The Shapiro-Wilk test was used to determine quantitative variables showing non-normal data distribution (p < 0.05), and are presented as median values, 25th and 75th percentiles and 95% confidence interval. The Student’s t-test and Wilcoxon test were used to analyze inter-group and intra-group expression of the biomarkers pre- and post-intervention. The Spearman test was used to analyze the correlation between the biomarkers. Stata version 11.0 was used for all analyses.

**Results**

This study included 14 hypertensive patients of equal numbers of each sex, 9 (64.3%) of whom were type 2 diabetics (T2DM), aged 44-64 years. There were three deaths due to non-cardiovascular events, one in the intervention group and two in the control group (Table 2). The difference between pre- and post-intervention (RIPC) levels of troponin I were not significant (p = 0.28). No significant difference was observed between the pre- and post-collection points for individual biomarkers. In addition, no difference was observed between the RIPC and control groups, except for IL-6 (p = 0.039), when analyzing the collection points and the presence or absence of RIPC (Table 3). The Spearman correlation test indicated a significant association (p = 0.56) between irisin and troponin I (Table 4).

| Table 1 | Primers sequence |
|---------|------------------|
| Gene    | Sequence         |
| GSH     | FOW 5‘CTACGGACCCATGGAGGAG 3’  
REV 5‘AGGCCATGGGACCTTCCT 3’  
FOW 5‘GTTTGGCCCTTCTCTCTCT 3’  
REV 5‘GCTCCTGTTGCTATTCTC 3’  
FOW 5‘GCCATTGGGATATATTGGA 3’  
REV 5‘CTCTTGACGGAATCGTCCAT 3’  
FOW 5‘CTCTTGACGGAATCGTCCAT 3’  
REV 5‘CTCTTTCCTTCCTCTCCCT 3’ |
| SE-P    | REV 5‘GCTCCTGTTGCTATTCTC 3’  
TRX1    | FOW 5‘CTCTTGACGGAATCGTCCAT 3’  
REV 5‘CATCCCATGGTGGACTACC 3’  
REV 5‘GATCCAGCGCATCAAGGACAT 3’  
REV 5‘TTGTGCAAAGCTAGCATTTGA 3’  
FOW 5‘CTCTTGACGGAATCGTCCAT 3’ |
| NF-κB   | REV 5‘CATCCCATGGTGGACTACC 3’  
Irisin  | FOW 5‘CTCTTGACGGAATCGTCCAT 3’  
REV 5‘GATCCAGCGCATCAAGGACAT 3’  
REV 5‘TTGTGCAAAGCTAGCATTTGA 3’  
GAPDH   | FOW 5‘CTCTTGACGGAATCGTCCAT 3’ |

| Table 2 | Demographic characteristics of the patients |
|---------|------------------------------------------|
| Variables | Patients (n = 14) |
| Gender (male) | 7 (50%) |
| Hypertension | 14 (100%) |
| Death | 3 (21.4%) |
| Diabetes | 9 (64.3%) |
| Age* | 52 (44 - 64) |

*Values expressed as mean and 95%CI.


**Table 3**  
**ASSOCIATION BETWEEN BIOMARKERS OF THE GROUP WITH AND WITHOUT REMOTE ISCHEMIC PRECONDITIONING (RIPC)**

| Biomarkers       | HD without RIPC | HD with RIPC | p*          |
|------------------|-----------------|--------------|-------------|
| Δ Ureia          | 64.00 (43.00; 107.80) | 61.00 (21.90; 115.80) | 0.051       |
| Δ Troponin I     | -0.01 (-0.03; 0.05) | 0.00 (-0.01; 0.01) | 0.361       |
| Δ TNF-α          | -0.30 (-3.51; 2.76) | 0.55 (-2.69; 9.61)  | 0.606       |
| Δ IL6            | -0.05 (-12.11; 2.54) | 5.50 (-1.15; 9.39)  | 0.039       |
| Δ Irisin         | 2.29 (-9.90; 14.47) | -1.40 (-14.61; 38.72) | 0.698       |
| Δ Tiorredoxin    | -1.53 (-23.80; 42.14) | -0.08; (-3.86; 7.53) | 0.439       |
| Δ NF-Kβ          | -0.66 (-31.81; 42.99) | 0.15 (-4.53; 6.95)  | 0.796       |
| Δ GPX4           | 1.06 (-2.52; 6.76)  | 1.26 (-2.55; 12.86) | 0.796       |
| Δ Selenoprotein  | 5.14 (-10.29; 39.05) | 0.61 (-12.89; 14.90) | 0.439       |

*Mann-Whitney’s; 95%CI: 95% confidence interval.

**Table 4**  
**CORRELATION BETWEEN SERUM BIOMARKERS**

| Biomarkers       | Irisin | Tiorredoxin | NF-Kβ | GPX4 | Selenoprotein |
|------------------|--------|-------------|-------|------|--------------|
|                  | Spearman's rho | p | Spearman's rho | p | Spearman's rho | p | Spearman's rho | p | Spearman's rho | p |
| Ureia            | 0.147  | 0.615       | -0.007 | 0.982 | 0.323 | 0.260 | 0.213 | 0.464 | 0.222 | 0.446 |
| Troponin I       | -0.171 | 0.558       | 0.082 | 0.780 | 0.284 | 0.325 | -0.246 | 0.396 | 0.242 | 0.405 |
| TNF-α            | 0.123  | 0.674       | -0.247 | 0.395 | -0.163 | 0.578 | -0.223 | 0.445 | 0.478 | 0.084 |
| IL6              | 0.393  | 0.164       | -0.108 | 0.714 | 0.090 | 0.759 | -0.503 | 0.067 | 0.125 | 0.670 |

**DISCUSSION**

This study aimed to establish the relationship between irisin expression and troponin I levels in hemodialysis patients submitted to RIPC. The negative correlation between these variables is in disagreement with the current literature. Hyperglycemic dogs submitted to intravenous dextrose or chemically induced diabetes showed an increase in the extent of myocardial infarction, in addition to annulling the protection resulting from preconditioning. These findings confirm preclinical and clinical evidence that elucidate the adverse interaction between hyperglycemia and cardioprotective pathways. Research conducted on rats, rabbits, dogs, sheep, and humans had very similar findings. This information may explain the lack of correlation found, since our sample was composed of diabetics (64.3%) and hypertensive patients (100%), in contrast to the literature, which consists of 40% diabetics and 32% hypertensive individuals. Disparate data likely occurred due to the small sample size.

In diabetic rats, the cardioprotective effect of RIPC was restored, increasing the number of cycles to obtain the desired effect, which indicates that diabetes increases the threshold for preconditioning. In a murine model of ischemia and reperfusion, it was the number and duration of the cycles, rather than the number of limbs exposed to RIPC that determined its effectiveness. The window of early protection disappeared between 1.5 and 2 hours after the end of the stimulus. In a study from 2018, hemodialysis patients submitted to RIPC for three successive sessions did not achieve myocardial protection compared to the control group; however, Park et al. did achieve such protection after twelve sessions. The inconsistency in these findings may be due to the number and/or duration of the sessions.

It has been suggested that poor cardioprotection in diabetics is due to the altered function of the ATP-dependent potassium channel (KATP channel) or the decrease in phosphorylation of important signaling kinases, including Akt (serine/threonine kinase protein) and glycogen synthase (GSK-3). Currently, prospective data support the possible role of inflammation in diabetogenesis, which is consistent with earlier hypotheses that type 2 diabetes mellitus may be a manifestation of the acute cytokine-mediated response of the innate immune system. In this scenario, positive associations were observed between IL-6 and PCR that remained after adjusting for body mass index, family history of diabetes, smoking, exercise,
alcohol use, and hormone replacement therapy. The multivariate relative risks for the highest versus the lowest quartiles were 2.3 for IL-6 (95% CI, 0.9-5.6, p tending toward = 0.07) and 4.2 for PCR (95% CI, 1.5-12.0, p tending toward = 0.001).38-39

Regarding mortality in the proposed six-month follow-up period, three (21.4%) non-cardiovascular deaths occurred, one in the intervention group and two in the control group. This corroborates data regarding the duration of hemodialysis that ascertained the relationship between the duration of hemodialysis therapy and mortality as a primary outcome in 11 countries; mortality rate (deaths/100 patient-years) was 16.9% (95% CI, 16.2-17.6) for a period of 121-365 days.40 In all countries, mortality was higher at baseline compared with the intermediate period, but the intermediate and late periods were similar. Within each period, a higher mortality occurred in the United States compared to most other countries. Thus, internationally, the initial period of hemodialysis constitutes the period of high risk in the countries studied, and substantial differences in mortality have been reported among these. In conclusion, independent of the time of collection, RIPC did not modify the levels of irisin and troponin I, even though both are known biomarkers.

**AUTHOR’S CONTRIBUTION**

FSG: conception, design and interpretation of data; writing of the article, critical review and approval of the version to be published.

MCG and CGMB: interpretation of data and writing of the article.

NM, BCAAR and FLAF: writing of the article, critical review and approval of the version to be published.

ECP: critical review and approval of the version to be published.

MRB: conception, writing of the article, critical review and approval of the version to be published.

**CONFLICT OF INTEREST**

The authors declare that they have no conflict of interest related to the publication of this manuscript.

**REFERENCES**

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis [Internet]. 2014 Jan; 63(1 Suppl):A7. Available from: https://doi.org/10.1053/j.ajkd.2013.11.001

2. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant. 1994;9(8):1136-42.

3. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 Dec 19;347(25):2010-9.

4. Jager DJ, Grootendorst DC, Jager KJ, Van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009 Oct 28;302(16):1782-9.

5. McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korshed S, Baker CS, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol. 2008 Jan;3(1):19-26.

6. Cheung AK, Sarnak MJ, Yan G, Berkhof M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int [Internet]. 2004 Jun; 65(6):2380-9. Available from: https://doi.org/10.1111/j.1523-1755.2004.00657.x

7. Ragosta M, Samady H, Isaacs RB, Gimple LW, Sarembock IJ, Powers ER. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am Heart J. 2004 Jun;147(6):1017-23.

8. Hasegawa M, Ishii J, Kitagawa F, Kanayama K, Takahashi H, Ozaki Y, et al. Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. Heart Vessels [Internet]. 2013 Jul; 28(4):473-9. Available from: https://doi.org/10.1007/s00380-012-0723-2

9. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol [Internet]. 2009 May; 4(5):914-20. Available from: https://doi.org/10.2215/CJN.03900808

10. McIntyre CW. Effects of hemodialysis on cardiac function. Kidney Int [Internet]. 2009 Aug 2; 76(4):371-5. Available from: https://doi.org/10.1038/ki.2009.207

11. Hausenloy DJ, Wmamoure PK, Venugopal V, Harris J, Barnard M, Grundy E, et al. Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007 Aug 18;370(9587):575-9.

12. Park J, Chung HC, Kim MS, Kim SJ, Chang JW, Lee JS. Relationship between extracellular water fraction of total body water estimated by bio-impedance spectroscopy and cardiac troponin T in chronic hemodialysis patients. Blood Purif [Internet]. 2009; 28(1):61-8. Available from: https://doi.org/10.1159/000210663

13. Otsuka T, Kawada T, Iibuki C, Seino Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. Am Heart J [Internet]. 2010 Jun; 159(6):972-8. Available from: https://doi.org/10.1016/j.ahj.2010.02.036

14. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature [Internet]. 2012 Jan 11; 481(7382):463-8. Available from: https://doi.org/10.1038/nature10777

15. Huh JY, Panagiotou G, Mougiou V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism [Internet]. 2012 Dec; 61(12):1725-1738. Available from: https://doi.org/10.1016/j.metabol.2012.09.002

16. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature [Internet]. 2012 Jan 11; 481(7382):463-8. Available from: https://doi.org/10.1038/nature10777
17. Tsuchiya Y, Ando D, Takamatsu K, Goto K. Resistance exercise induces a greater irisin response than endurance exercise. Metabolism [Internet]. 2015 Sep; 64(9):1042-50. Available from: https://doi.org/10.1016/j.metabol.2015.05.010

18. Nygaard H, Sikkalokken G, Vegge G, Hoffan I, Whist JE, Strand T, et al. Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training. PLoS One [Internet]. 2015 Mar 17; 10(3):e0121367. Available from: https://doi.org/10.1371/journal.pone.0121367

19. Chen N, Li Q, Liu J, Jia S. Irisin, an exercise-induced myokine as a metabolic regulator: an updated narrative review. Diabetes Metab Res Rev [Internet]. 2016 May; 32(1):51-9. Available from: https://doi.org/10.1002/dmr.2660

20. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab [Internet]. 2013 Apr; 98(4):E769-78. Available from: https://doi.org/10.1210/jc.2012-2749

21. Kharbanda RK, Nielsen TT, Redington AN. Translation of remote ischemic preconditioning into clinical practice. Lancet [Internet]. 2009 Oct 31; 374(9700):1557-65. Available from: https://doi.org/10.1016/S0140-6736(09)61421-5

22. Hoole SP, Heck PM, Shariples L, Khan SN, Duehmke R, Denno CG, et al. Remote ischemic preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation [Internet]. 2009 Feb 2; 119(6):820-7. Available from: https://doi.org/10.1161/CIRCULATIONA-HA.108.809723

23. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, et al. Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. Lancet [Internet]. 2007 Aug 18; 370(9587):575-579. Available from: https://doi.org/10.1016/S0140-6736(07)61296-3

24. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Wartliert DC. Acute hyperglycemia abolishes ischämische preconditioning in vivo. Am J Physiol. 1998 Aug275(2 Pt 2):H721-5.

25. Kersten JR, Toller WG, Gross ER, Pagel PS, Wartliert DC. Diabetes abolishes ischämische preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1218-24.

26. Tosaki A, Engelman DT, Engelman RM, Das DK. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res. 1996c;31:526-536.

27. Wider J, Undyala VVR, Whittaker P, Woods J, Chen X, Przybylensk K. Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication. Basic Res Cardiol [Internet]. 2018 May; 113(3):16. Available from: https://doi.org/10.1007/s00395-018-0674-1

28. Del Valle HF, Lascano EC, Negroni JA, Crottogini AJ. Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction. Mol Cell Biochem. 2003 Jul;249(1-2):21-30.

29. Moretti C, Cerarre E, Cavalleri E, Lin S, Rossi ML, Picchi A, et al. The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trial. Int J Cardiol [Internet]. 2018 Apr 15; 257:1-6. Available from: https://doi.org/10.1016/j.ijcard.2017.12.033

30. Saran R, Robinson B, Abbott KC, Agodaa LYC, Bhaive N, Bragg-Gresham J, et al. US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis [Internet]. 2018 Mar; 71(3 Suppl 1):A7. Available from: https://doi.org/10.1053/j.ajkd.2018.01.002

31. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes [Internet]. 2005 Aug; 54(8):2360-2364. Available from: https://doi.org/10.2337/db04-1352

32. Johansen J, Pydys K, Salmon R, Lotgiren B, Kristiansen SB, Bortker HE. The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol [Internet]. 2016 Mar; 111(2):10. Available from: https://doi.org/10.1007/s00395-016-0529-9

33. Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ. The diabetic heart: too sweet for its own good?. Cardiol Res Pract [Internet]. 2012; 2012:845698. Available from: https://doi.org/10.1155/2012/845698

34. Bacci MR, Vasconcelos LY, Murad N, Chagas AC, Capuano AC, Alves BC, et al. Remote ischemic preconditioning in myocardial protection in hemodialysis patients. Int J Gen Med [Internet]. 2015 May 8; 11:175-178. Available from: https://doi.org/10.2147/IJGM.S144385

35. Park J, Ann SH, Chung HC, Lee JS, Kim SJ, Garg S, et al. Remote ischemic preconditioning in hemodialysis: a pilot study. Heart Vessels [Internet]. 2014 Jan; 29(1):58-64. Available from: https://doi.org/10.1007/s00380-013-0329-0

36. Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial ischemia-reperfusion injury in the isolated rat heart. Acta Physiol Scand. 2010 Jul; 199(3):H1718-24.

37. Peng J, Tjandra S, Yellon DM. The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol [Internet]. 2012 Jun 13; 11(6):1-13. Available from: https://doi.org/10.1007/s00395-016-0529-9

38. Jhaveri GC, Shukla A, Shukla P, Malla SC, Sharma P, Prasad SK, et al. Remote ischemic preconditioning: a potential strategy for cardiac protection in hemodialysis patients. Indian Heart J [Internet]. 2014 May; 66(5):435-439. Available from: https://doi.org/10.4103/0019-5049.143644

39. Grossmann V, Schmitt VH, Zeller T, Panova-Noeva M, Schulz A, Laubert-Reh D, et al. Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes. Cardiovascular Diabetol [Internet]. 2012 Jun 13; 11(6):1-13. Available from: https://doi.org/10.1186/1475-2840-11-67

40. Robinson BM, Zhang J, Morgenstern H, Bradbury BD, Ng LJ, McCullough KP, et al. World-wide, mortality is a high risk soon after initiation of hemodialysis. Kidney Int [Internet]. 2014 Jan; 85(1):158-65. Available from: https://doi.org/10.1038/ki.2013.252